085660.KQ Chabiotech Co.,Ltd.
KOEHealthcareAs of 2026-08-09 03:17
Why 085660.KQ matters now
Chabiotech Co.,Ltd. (085660.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩9,300.00 with +0.22% on the session and ₩864.65B in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E -7.85, gross margin 26.9%, and operating margin -5.2%.
Valuation
P/E (TTM)
-7.85
PEG
—
P/B
1.61
P/S
0.54
EV/EBITDA
-32.12
DCF Value
—
FCF Yield
-41.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
26.9%
Operating Margin
-5.2%
Net Margin
-5.7%
ROE
-19.2%
ROA
-2.6%
ROIC
-3.1%
Listing Info
Market
Korea
Exchange
KOE
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
Chabiotech Co.,Ltd. is a global biotechnology firm specializing in the development of cell and gene therapies, particularly those involving stem and immune cells, with operations in South Korea and internationally. The company's comprehensive offerings include umbilical cord blood storage for treating intractable conditions, alongside various regenerative medicine solutions. It also manages storage services for immune and stem cells, provides anti-aging treatments, and delivers therapeutic solutions for debilitating illnesses. Furthermore, Chabiotech runs medical wellness initiatives encompassing fitness, spa services, and nutritional supplements. Leveraging its extensive research and development as well as clinical expertise, the company provides customized services covering product development, manufacturing, clinical trials, and commercialization. Chabiotech assists clients with optimizing IT system infrastructure and operations, and offers consulting services for the establishment, management, and growth of its proprietary Chaum model. Additionally, the company provides solutions for maternal-focused genomic testing and personalized healthcare. It is actively engaged in developing advanced immune cell therapies, such as CBT101 for recurrent glioblastoma and solid cancers, and both CBT111 and CAR-NK treatments specifically targeting solid tumors. Its stem cell pipeline features CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for addressing macular degeneration and Stargardt's disease. Beyond its core bio-pharmaceutical activities, Chabiotech also offers IVF (fertility) services, manufactures cosmetics and their raw materials, supplies medical devices, provides bioinsurance storage, and conducts various research services. Established in 2002, the company maintains its headquarters in Seoul, South Korea.